FDG positron emission tomography imaging of drug-induced pneumonitis

Abstract

Several studies have reported the findings of fluorine-18-labeled fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) in benign lung disease with diffuse pulmonary injury; however, the characteristics and effectiveness of FDG-PET imaging for interstitial pneumonitis have not been substantiated. We report two cases of drug-induced pneumonitis in two patients treated for breast cancer who were diagnosed by FDG-PET examination. Both the cases showed diffuse interstitial infiltration in the bilateral lungs on computed tomography, but the degree of FDG accumulation was different. It is probable that the degree of FDG accumulation reflected the activity of the drug-induced pneumonitis. The present cases show very interesting FDG-PET imaging findings of diffuse lung disease.

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane

“…Previous studies have demonstrated that a high everolimus trough concentration is associated with a higher risk of toxicity [14,28]. Increased FDG-avidity in the lungs on FDG-PET scans has been reported in several patients with drug-induced ILD such as bleomycin, rituximab, etoposide, and paclitaxel, mostly as diffuse bilateral FDG-accumulation [29][30][31][32][33][34][35]. FDG-PET has been reported to detect ILD earlier than high resolution computed tomography [36].…”

Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia

“…[ 18 F]-2-fluoro-2-deoxy-D-glucose positron emission tomography ( 18 F-FDG PET) is an imaging modality that detects the increased uptake of glucose in areas of increased cell metabolism. This technique is most often applied for diagnosis of malignancy, although it has also been found useful for detection of benign diseases [5], such as bronchiolitis obliterans organizing pneumonia (BOOP) [6], IPF [7], and drug-induced pneumonitis [8].…”

Pulmonalis eltérések Hodgkin-lymphomában

“…Több esetet közöltek, amelyben a 18 FDG-PET/CT hasznos diagnosztikus eszköznek bizonyult a bleomycin indukálta tüdőkárosodás korai felismerésében [20,21]. A légzésfunkciós vizsgálatok és a konvencionális CTvizsgálat nem képes azonosítani a bleomycin indukálta gyulladás metabolikus aktivitását, viszont a 18 FDG-PET/ CT a metabolikus eltérések azonosítására is alkalmas, így lehetőséget teremt az aktív gyulladás és a residualis roncsolás megkülönböztetésére.…”